162 related articles for article (PubMed ID: 17646850)
1. Transcriptional profiling of transurethral resection samples provides insight into molecular mechanisms of hormone refractory prostate cancer.
Stoss O; Werther M; Zielinski D; Middel P; Jost N; Rüschoff J; Henkel T; Albers P
Prostate Cancer Prostatic Dis; 2008; 11(2):166-72. PubMed ID: 17646850
[TBL] [Abstract][Full Text] [Related]
2. Prostate stem cell antigen mRNA expression in preoperatively negative biopsy specimens predicts subsequent cancer after transurethral resection of the prostate for benign prostatic hyperplasia.
Zhao Z; Liu J; Li S; Shen W
Prostate; 2009 Sep; 69(12):1292-302. PubMed ID: 19462463
[TBL] [Abstract][Full Text] [Related]
3. Transcriptome analyses of benign and malignant prostate epithelial cells in formalin-fixed paraffin-embedded whole-mounted radical prostatectomy specimens.
Furusato B; Shaheduzzaman S; Petrovics G; Dobi A; Seifert M; Ravindranath L; Nau ME; Werner T; Vahey M; McLeod DG; Srivastava S; Sesterhenn IA
Prostate Cancer Prostatic Dis; 2008; 11(2):194-7. PubMed ID: 17768422
[TBL] [Abstract][Full Text] [Related]
4. Differential gene expression in the peripheral zone compared to the transition zone of the human prostate gland.
Noel EE; Ragavan N; Walsh MJ; James SY; Matanhelia SS; Nicholson CM; Lu YJ; Martin FL
Prostate Cancer Prostatic Dis; 2008; 11(2):173-80. PubMed ID: 17646851
[TBL] [Abstract][Full Text] [Related]
5. Gene amplifications associated with the development of hormone-resistant prostate cancer.
Edwards J; Krishna NS; Witton CJ; Bartlett JM
Clin Cancer Res; 2003 Nov; 9(14):5271-81. PubMed ID: 14614009
[TBL] [Abstract][Full Text] [Related]
6. A candidate molecular signature associated with tamoxifen failure in primary breast cancer.
Vendrell JA; Robertson KE; Ravel P; Bray SE; Bajard A; Purdie CA; Nguyen C; Hadad SM; Bieche I; Chabaud S; Bachelot T; Thompson AM; Cohen PA
Breast Cancer Res; 2008; 10(5):R88. PubMed ID: 18928543
[TBL] [Abstract][Full Text] [Related]
7. Androgen deprivation therapy affects BCL-2 expression in human prostate cancer.
Fuzio P; Ditonno P; Lucarelli G; Battaglia M; Bettocchi C; Senia T; Perlino E
Int J Oncol; 2011 Nov; 39(5):1233-42. PubMed ID: 21785821
[TBL] [Abstract][Full Text] [Related]
8. PSCA mRNA expression in preoperatively negative prostate biopsies predicts incidental prostate cancer in patients undergoing transurethral resection of the prostate for benign prostatic hyperplasia.
Zhao Z; Ma W; Zeng G; Qi D
J Surg Oncol; 2011 Nov; 104(6):672-8. PubMed ID: 21674503
[TBL] [Abstract][Full Text] [Related]
9. Preimplant predictive factors of urinary retention after iodine 125 prostate brachytherapy.
Mabjeesh NJ; Chen J; Stenger A; Matzkin H
Urology; 2007 Sep; 70(3):548-53. PubMed ID: 17905113
[TBL] [Abstract][Full Text] [Related]
10. Molecular determinants of resistance to antiandrogen therapy.
Chen CD; Welsbie DS; Tran C; Baek SH; Chen R; Vessella R; Rosenfeld MG; Sawyers CL
Nat Med; 2004 Jan; 10(1):33-9. PubMed ID: 14702632
[TBL] [Abstract][Full Text] [Related]
11. Molecular features of hormone-refractory prostate cancer cells by genome-wide gene expression profiles.
Tamura K; Furihata M; Tsunoda T; Ashida S; Takata R; Obara W; Yoshioka H; Daigo Y; Nasu Y; Kumon H; Konaka H; Namiki M; Tozawa K; Kohri K; Tanji N; Yokoyama M; Shimazui T; Akaza H; Mizutani Y; Miki T; Fujioka T; Shuin T; Nakamura Y; Nakagawa H
Cancer Res; 2007 Jun; 67(11):5117-25. PubMed ID: 17545589
[TBL] [Abstract][Full Text] [Related]
12. Overexpression and gene amplification of BAG-1L in hormone-refractory prostate cancer.
Mäki HE; Saramäki OR; Shatkina L; Martikainen PM; Tammela TL; van Weerden WM; Vessella RL; Cato AC; Visakorpi T
J Pathol; 2007 Aug; 212(4):395-401. PubMed ID: 17503439
[TBL] [Abstract][Full Text] [Related]
13. Longitudinal analysis of androgen deprivation of prostate cancer cells identifies pathways to androgen independence.
D'Antonio JM; Ma C; Monzon FA; Pflug BR
Prostate; 2008 May; 68(7):698-714. PubMed ID: 18302219
[TBL] [Abstract][Full Text] [Related]
14. Renin-angiotensin system is an important factor in hormone refractory prostate cancer.
Uemura H; Hasumi H; Ishiguro H; Teranishi J; Miyoshi Y; Kubota Y
Prostate; 2006 Jun; 66(8):822-30. PubMed ID: 16482568
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms of prostate cancer progression to androgen independence.
McPhaul MJ
Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):373-88. PubMed ID: 18471793
[TBL] [Abstract][Full Text] [Related]
16. Hormonal regulation of beta2-adrenergic receptor level in prostate cancer.
Ramberg H; Eide T; Krobert KA; Levy FO; Dizeyi N; Bjartell AS; Abrahamsson PA; Taskén KA
Prostate; 2008 Jul; 68(10):1133-42. PubMed ID: 18454446
[TBL] [Abstract][Full Text] [Related]
17. Signal transducer and activator of transcription-6 (STAT6) is a constitutively expressed survival factor in human prostate cancer.
Das S; Roth CP; Wasson LM; Vishwanatha JK
Prostate; 2007 Oct; 67(14):1550-64. PubMed ID: 17705178
[TBL] [Abstract][Full Text] [Related]
18. [Gene expression profile in hormone refractory prostate cancer].
Stoss O; Jost N; Czeloth K; Rüschoff J; Henkel T; Albers P
Urologe A; 2007 Sep; 46(9):1117-9. PubMed ID: 17639295
[No Abstract] [Full Text] [Related]
19. Drug insight: role of the androgen receptor in the development and progression of prostate cancer.
Taplin ME
Nat Clin Pract Oncol; 2007 Apr; 4(4):236-44. PubMed ID: 17392714
[TBL] [Abstract][Full Text] [Related]
20. Identification of mu-crystallin as an androgen-regulated gene in human prostate cancer.
Malinowska K; Cavarretta IT; Susani M; Wrulich OA; Uberall F; Kenner L; Culig Z
Prostate; 2009 Jul; 69(10):1109-18. PubMed ID: 19353593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
